All News

DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus

d Jack Cush, MD

Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).

Read Article
steroid prednisone lab

Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency

d Jack Cush, MD

Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility.

Read Article
kidneys

Best of 2024: Efficacy of Biologics in Patients with Chronic Kidney Disease

d Jack Cush, MD

A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis patients with chronic kidney disease, shows the 3 year survival to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy.

Read Article
ild.jpg

Best of 2024: 13 Risk Factors for RA-associated Interstitial Lung Disease

d Jack Cush, MD

Interstitial lung disease (ILD) is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). A recent metanalysis shows the pooled prevalence of RA-ILD was approximately 18.7%.

Read Article
SI.Sacroiliitis.AS_.jpg

Best of 2024: ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis

d Jack Cush, MD

Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.

Read Article
Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/f7OwxAggaf… https://t.co/PUuwo0MLso https://t.co/JBzokT9icx

Links:

Dr. John Cush RheumNow ( View Tweet)
Should you worry about giving TNFi to RA pts after a cancer diagnosis? Medicare data with colorectal, lung, prostate Ca: TNFi pts survival no worse (numerically better) than csDMARDs Cancer pts deserve good RA treatment! #ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow… https://t.co/aR75hJQ6YK https://t.co/ptDYCsOpXN
Dr. John Cush RheumNow ( View Tweet)
ANA neg, but ENA pos should we care about that result? PPV 5.5% here (similar to 6% prev @EricFMorand: https://t.co/7Lo0DgHtXT) and how many really needed the serology? Anxiety? Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️ #ACR24 ABST1930 @RheumNow… https://t.co/lZ1TJxTqhs https://t.co/itx0TCFFjl

Links:

Dr. John Cush RheumNow ( View Tweet)
Great table re:side effects of even low dose steroids in RA Likely generalizes to other diseases ie PMR, SLE P in prednisone stands for poison! #ACR24 @RheumNow https://t.co/2bFy6dwl96 https://t.co/YDtjSX054I

Links:

Dr. John Cush RheumNow ( View Tweet)
TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/F9DOBLrjVq https://t.co/BtphAuEopA

Links:

Dr. John Cush RheumNow ( View Tweet)
54K Peptic Ulcers Annually (12.13.2024) https://t.co/18FiQx1YQA https://t.co/32UZi9XafS

Links:

Dr. John Cush RheumNow ( View Tweet)
Improvements in Pain and Fatigue in Bimekizumab Dr. Philip Mease discusses abstract 2368, presented at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/ON09z9yTuJ https://t.co/650TUdHwYm

Links:

Dr. John Cush RheumNow ( View Tweet)
Vaccine Responses:The DMARD Counts Dr. David Liew reviews abstracts 0247, 0248, 1988, 1009, reporting from Melbourne, Australia for the 2024 ACR Convergence meeting. https://t.co/0qDGRkT64B https://t.co/dO9EvhD1NE

Links:

Dr. John Cush RheumNow ( View Tweet)
How do you manage skin in Sscl? -RNA pol III + high risk for skin progression. -Limited+ low risk + stable Sscl no need for immunesuppresors. -Look for EF in pts with generalized morphea. -Ttnt of skin depending on other organ involvements. -If no Raynaud’s/hands spared think of… https://t.co/DZzhShKzS8 https://t.co/J9Qg1Lk2Wl
Dr. John Cush RheumNow ( View Tweet)
#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/g3egOpCYNr https://t.co/KMiOEP7pSg
Dr. John Cush RheumNow ( View Tweet)
Sarcoidosis is biopsy supported not proven” -Dx is clinical with broad ddx. -Assess organ involvement in all pts. -Whole body PET can help assess disease activity (not in CNS disease) -MR brain with pituitary cuts helpful in CNS sarcoid. #ACR24 @ACRheum @RheumNow… https://t.co/Ka1cHtFOqj

Dr. John Cush RheumNow ( View Tweet)

RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease: ➡️ A. Ogdie: Preventing PsA ➡️ A. Kavanaugh: Biologic Therapies ➡️ K. Gordon: Head-to-Head Studies Register now! https://t.co/9qnqtpkwpT https://t.co/95TGS56vyA

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease https://t.co/Sd3H5Tzhtf https://t.co/guXzL5bc6R

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Analgesic Prescribing in Patients with Inflammatory Arthritis https://t.co/iQrBVzWaI8 https://t.co/Rx86Q57oEZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Bah Humbug Vitamin D (12.20.2024) https://t.co/Mjuk6buRsX https://t.co/aX8cetkbWc

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×